RALEIGH — Merz, a global healthcare company, today announced plans to reorganize into three independently operating businesses: medical aesthetics, therapeutics and consumer care.
Under this structure, Merz Aesthetics said it will be the largest “dedicated medical aesthetics business” globally.
The announcement comes on the back of solid year for the company, growing 6.8 percent year-on-year. That was largely driven, it said, by a 17 percent hike in the aesthetics business.
Merz Aesthetics global management team will now be based in Raleigh, North Carolina.
Merz will start operating in the new structure January 1, 2020.
As part of this reorganization, Bob Rhatigan has been appointed global chief executive officer of Merz Aesthetics, assuming responsibility for all aspects of the global aesthetics business.
Rhatigan previously served as CEO of Merz Americas. “He has driven both Xeomin (incobotulinumtoxinA) and Ultherapy to double-digit growth, making Xeomin one of the fastest growing neurotoxin in the U.S. medical aesthetics market, and more than doubled Merz’s flagship injectable filler, Radiesse, in Latin America,” the firm said in its release.
Merz is part of the Merz Pharma Group, a privately owned health care company based in Frankfurt, Germany, with about 3,000 employees worldwide. The company had global sales of just over 1 billion euros in 2017-18, with North America sales accounting for almost a third of the total.
Merz’s North America headquarters in North Raleigh employs about 300 people and is located in a 60,000 square-foot facility on Six Forks Road. It had been based in Greensboro from 1995 to January 2015, when it consolidated operations in Raleigh.
The company also has manufacturing and distribution facilities in Mesa, Ariz., and Franksville, Wis.
Merz receives FDA approval for involuntary blinking treatment
